Studies have revealed the downregulation of PGC1α expression, particularly in the advanced stages of thyroid cancer (19) and notably in tumors harboring the BRAF V600E mutation (17), which is the most prevalent somatic oncogenic mutation in papillary thyroid carcinoma (20, 21). This evidence concerns the gene PPARGC1A and thyroid gland carcinoma.